Nuvectis Pharma, Inc. (NVCT)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $18.15
- As of
Kresmion compiles this page from NVCT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Nuvectis Pharma, Inc. (NVCT): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-21.
See the full NVCT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NVCT on one page. Preview it with sample data, then open it live with a free account.
Preview the NVCT dossierActive signals for NVCT
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +252% to NVCT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +697% to NVCT (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 12.3%, EPS $-0.30 vs $-0.2672 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 15.3% - EPS $-0.3 vs $-0.2601 estimate
- mediumEARNINGS_MISS
Q3-2025: Missed consensus by 30.7% - EPS $-0.33 vs $-0.2525 estimate
FREE, NO ACCOUNT
Every signal on NVCT, as it fires
You are seeing 5 of 6 signals recorded on NVCT since 2026-05-31.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NVCT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 67080T108 · 2026Q2 | $2.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NVCT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
NVCT against its peers
NVCT's return on equity of -143.6% ranks in the 17th percentile of 20 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | NVCT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 42.7M | n/a | 17 |
| Operating margin | n/a | -93.0% | n/a | 16 |
| Net margin | n/a | -120.0% | n/a | 16 |
| Return on equity | -143.6% | -52.5% | 17 | 20 |
| 1 year | 193.2% | -11.3% | 88 | 20 |
Peers (22): PHAT, DBVT, SGMT, CRMD, STTK, IRWD, CLYM, VALN, CTMX, AURA, SLN, WVE, OLMA, CBIO, PRME, PBYI, ZVRA, ALLO, RGNX, MNPR, PHAR, VSTM. Left out: ETRA (no annual filing), BLSM (no annual filing), DRUG (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (NVCT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NVCT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NVCT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.